北大医药(000788) - 2022 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2022 was ¥555,998,229.24, a decrease of 5.78% compared to the same period last year[5] - Net profit attributable to shareholders was ¥15,941,378.28, down 29.44% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥14,411,779.72, a decline of 36.36% compared to the previous year[5] - The total revenue for the third quarter of 2022 was CNY 1,556,984,364.28, a decrease of 8.06% compared to CNY 1,693,912,427.73 in the same period last year[34] - The net profit for the third quarter of 2022 was CNY 45,770,236.78, a decline of 17.54% from CNY 55,518,176.84 in the same quarter of the previous year[35] - The total comprehensive income for the third quarter was CNY 45,770,236.78, a decrease from CNY 55,518,176.84 in the same period last year[36] - Basic and diluted earnings per share were both CNY 0.0768, down from CNY 0.0931 year-over-year[36] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥47,315,539.92, an increase of 92.34% year-on-year[8] - Cash inflow from operating activities totaled CNY 1,741,366,572.33, compared to CNY 1,805,515,693.93 in the previous year, reflecting a decline of approximately 3.55%[38] - The net cash flow from operating activities was CNY 47,315,539.92, an increase from CNY 24,600,318.25 in the same period last year[38] - Cash and cash equivalents as of September 30, 2022, were CNY 435,238,820.88, down from CNY 446,260,598.94 at the beginning of the year, representing a decrease of 2.29%[31] - Cash and cash equivalents at the end of the period were CNY 347,759,764.89, down from CNY 354,663,817.40 year-over-year[38] - The company reported a cash outflow of CNY 43,251,358.64 from financing activities, compared to -CNY 25,572,955.19 in the same period last year[38] - The company received CNY 110,858,307.68 in other operating cash, significantly higher than CNY 46,682,576.63 in the previous year[37] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,528,981,527.31, a decrease of 0.48% from the end of the previous year[5] - The total assets as of September 30, 2022, were CNY 2,528,981,527.31, slightly down from CNY 2,541,299,544.68 at the beginning of the year, a decrease of 0.48%[33] - The total liabilities decreased to CNY 1,162,297,366.50 from CNY 1,206,677,909.88, reflecting a reduction of 3.68%[33] Research and Development - Research and development expenses decreased by 68.19% to ¥6,257,913.86 for the first nine months of 2022[8] - The company's R&D expenses for the third quarter of 2022 were CNY 6,257,913.86, significantly lower than CNY 19,671,088.05 in the same period last year, a decrease of 68.17%[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 65,402[10] - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., holds 27.00% of the shares, totaling 160,896,260 shares[10] - The company’s major shareholders include Southwest Synthetic Pharmaceutical Group Co., Ltd., holding 160,896,260 shares, and Peking University Medical Industry Group Co., Ltd., holding 70,328,949 shares[11] Regulatory Approvals and Corporate Actions - The company received approval from the National Medical Products Administration for the chemical drug "Trimebutine Hydrochloride Sustained-Release Tablets" on January 11, 2022[12] - The company received approval from the National Medical Products Administration for the chemical drug "Compound Sulfamethoxazole Tablets," which passed the consistency evaluation of quality and efficacy for generic drugs[18] - The company obtained the drug registration certificate for "Olanzapine Tablets" from the National Medical Products Administration on July 21, 2022[25] - The company signed a supplementary agreement for a counter-guarantee contract with the related guarantor, achieving substantial progress in mitigating related guarantee risks[14] - The company reported that as of March 31, 2022, it had fully withdrawn RMB 243 million in deposits and interest from the financial company of the parent group, resolving related deposit risk issues[17] Market Activities - The company participated in the seventh batch of national centralized drug procurement on July 12, 2022, with plans to bid for "Cefminox Sodium Injection" and "Meropenem Injection," which passed the consistency evaluation[25] - The company disclosed a report on acquisitions on February 23, 2022, detailing its strategic moves in the market[15] - China International Capital Corporation was appointed as the financial advisor for the acquisition of the company by Beijing Medical Management Co., Ltd., with a continuous supervision period lasting 12 months from February 23, 2022[28] Stock Trading and Shareholder Changes - The company’s stock experienced abnormal trading fluctuations, with cumulative price deviations exceeding 20% on multiple occasions in March 2022[16] - On May 12, 2022, the shareholder Synthetic Group reduced its holdings by 3,500,000 shares, accounting for 0.5873% of the total share capital, leaving it with 166,856,260 shares, or 27.9966% of the total[19] - On May 17, 2022, the Synthetic Group further reduced its holdings by 2,461,400 shares, representing 0.4130% of the total share capital, bringing its total holdings down to 164,394,860 shares, or 27.5836%[20] - As of May 18, 2022, the Synthetic Group's cumulative reduction reached 2,980,000 shares, accounting for 0.5% of the total share capital, indicating that more than half of the planned reduction had been executed[21] - The Synthetic Group underwent a change in shareholder structure, now being a wholly-owned subsidiary of Fangzheng Commercial Management Co., Ltd., as of August 26, 2022[26] - The company received a notice on August 31, 2022, regarding the Synthetic Group's plan to further reduce its holdings[27]